Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medtronic Inc's CRT devices now approved to Treat Patients with AV Block and Reduced Heart Function


Thursday, 10 Apr 2014 07:08pm EDT 

Medtronic Inc:Announces U.S. Food and Drug Administration approved an expanded indication for biventricular pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators.Medtronic CRT devices are now approved to treat patients with atrioventricular block and left ventricular systolic dysfunction, reducing heart failure hospitalizations and mortality, and improving cardiac function in these patients.FDA's approval was based on the BLOCK HF clinical trial, which demonstrated significant clinical advantages of BiV pacing compared with traditional right ventricular (RV) pacing in this patient population. 

Company Quote

72.49
0.41 +0.57%
21 Nov 2014